Hepatitis B Vaccine...aluminium....thimerosal (mercury)....yeast...but don't worry, it's gluten free!

Report by Orissadiary correspondent; Bhubaneswar: At least 18 children were hospitalised on Saturday after being administered the Hepatitis B vaccine at a health camp in Totapada village near Khurda by an NGO 'Naibedya'. Around 50 children were given the injection. 18 of them suddenly fell ill and were admitted to the district headquarter hospital after complaints of head reeling and vomiting. Secretary, Health and Family Welfare Anu Garg said an inquiry has been ordered.

Hepatitis B Vaccination of Male Newborns Causes Autism! Boys Vaccinated At Birth With Hep B Have 3 Times Greater Risk.

At Birth Hepatitis B Vaccine Causes Developmental Delay in Baby Monkeys

A new research study published today in a leading scientific journal, NeuroToxicology, found that a Hepatitis B vaccine containing the mercury-based preservative thimerosal caused significant delays in the acquisition of critical survival reflexes in newborn rhesus macaque monkeys. In this first-ever study comparing vaccinated animals with unvaccinated controls, thirteen of the animals were given a Hepatitis B vaccine containing a standardized amount of thimerosal to match that given to babies; four received a saline placebo, and three were not given any shots. The unvaccinated animals developed normally. Delays in vaccinated infants involved three critical reflexes associated with feeding, which are essential for survival in the wild.

Hep B Vaccine Doesn't Work in Patients with Celiac Disease. 50% of Sufferers were Unresponsive to Vaccination

Human leukocyte antigen (HLA) phenotype DQ2 is considered the most important genetic marker for un-responsiveness to hepatitis B vaccine. Since celiac disease (CD) is also strongly associated with the same haplo-type it may be hypothesized that celiac patients are less able to respond to the vaccine. We report a retrospective study on celiac patients vaccinated with three doses of 10 μg at 3, 5 and 11 months of age by an intramuscular injection of a recombinant hepatitis B vaccine (Engerix B).

Lupus After Hep B Vaccination

The objective of this article is to identify common and atypical features of systemic lupus erythematosus diagnosed following hepatitis B vaccination. We analyzed retrospectively the medical records of 10 systemic lupus erythematosus patients from different centers, who developed the disease following hepatitis B vaccination and determined the prevalence of different manifestations and the time association to vaccination. In this case series, 80% of the patients were female, mean age 35 ± 9 years, of which 20% received one inoculation, 20% received two doses and 60% received all three inoculations. The mean latency period from the first hepatitis B virus immunization and onset of autoimmune symptoms was 56.3 days. All patients were diagnosed with systemic lupus erythematosus, according to the American College of Rheumatology revised criteria within 1 year. The prevalence of some systemic lupus erythematosus manifestations was typical and included involvement of the joints (100%), skin (80%), muscles (60%) and photosensitivity (30%). Other symptoms differed in this unique group of systemic lupus erythematosus patients such as low rate of kidney and hematologic involvement, and a relatively high rate of hepatitis (20%). Neurological (80%) and pulmonary (70%) symptoms were also common in this group. Data from this case-series, and previously documented cases in the literature could only show a temporal relation between hepatitis B vaccination and the appearance of systemic lupus erythematosus. Systemic lupus erythematosus related to vaccine may differ from idiopathic systemic lupus erythematosus in its clinical presentation and may resemble drug-induced systemic lupus erythematosus. Thus, physicians should be alerted to this potential association, its possible long latency period and unique presentations, and be encouraged to report and analyze these cases. Lupus (2009) 18, 1192—1197.

Anaphylactic shock due to hepatitis B immunoglobulin in a newborn

Hepatitis B immunoglobulin (HBIG) is administered for the passive immunisation of all infants born to HBsAg-positive mothers within 12h of birth. Adverse effects of HBIG are very rare. In this study, we report a newborn (a female, 33 weeks' gestation and 2030g birth weight) developing anaphylaxis after HBIG administration. The mother was a Hepatitis B virus (HBV) carrier. Hypotension and erythematous rash developed 7min after HBIG administration. Reporting the first anaphylaxis case in newborns due to HBIG in literature, we suggest the condition be taken into account, and requisite precautions should be taken against this probable complication in the newborn.

44 Pupils Sick and Hospitalised after Hepatitis B Vaccine

Babies of Hep B Positive Mothers Still Getting Hep B Despite Vaccination

About 10 percent of babies born to mothers with the hepatitis B e antigen (HBeAg) will become HB carriers, even with vaccination, a pediatrician said Saturday.

Since the HB vaccine does not guarantee full protection against infection, it is important to keep track of high risk children, said Chen Hui-ling, a pediatrician at National Taiwan University Hospital.

Citing a study of some 2,000 some children, Chen said that infants born to HBeAg mothers have a higher chance of becoming carriers, even if a rigorous vaccination scheme is implemented 24 hours after birth.

Source: Focus Taiwan News Channel, 21st July 2012.

FDA does not endorse the safety of a new hepatitis b vaccine

In Maryland, a federal advisory panel has voted not to support the safety of a novel hepatitis B vaccine for adults aged 18 to 70 years according to Medscape.com's Medical News. At a meeting on Thursday, the United States Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee voted 8 to 5 with 1 abstention that the safety data presented by Dynavax Technologies Corporation were not adequate to support safety of Heplisav.

2. That the vaccine hadn't been studied in sufficient numbers of ethnic minority populations

3. That it hadn't been studied in combination with the administration of other adult vaccines.

There were numerically greater numbers of Heplisav patients with evidence of autoimmunity including thyroid disorders, and some rare serious events among Heplisav recipients, including 1 case each of Wegener's granulomatosis, Tolosa-Hunt syndrome, and Guillain-Barre syndrome. Melinda Wharton, deputy director of the National Center for Immunization and Respiratory Diseases at the Centers for Disease Control and Prevention, Atlanta, Georgia, voted no for safety. She said, "...I don't think the safety database is sufficiently large to support a recommendation for use in the general adult population, given that this vaccine contains a new adjuvant."

Committee chairman and professor of pediatrics and microbiology and molecular medicine at the University of Chicago, Illinois, Robert Daum, MD, voted no on both efficacy and safety. "I'm concerned that there are not enough data in different ethnic groups to be sure that the immunogenic responses are adequate. I'm also concerned that there were no data presented about giving other vaccines simultaneously.... If this were a pediatric vaccine we'd be jumping up and down about that.... I don't see this as a separate visit vaccine," said Dr. Daum. Bruce Gellin, MD, MPH, director of the National Vaccine Program Office of the US Department of Health and Human Services, also voted no for safety.